Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA. In cancer, many of the proteins that regulate these modifications can be altered in both function and expression. One example of this is the family of histone deacetylas...
Main Authors: | Mario Federico, Luigi Bagella |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Journal of Biomedicine and Biotechnology |
Online Access: | http://dx.doi.org/10.1155/2011/475641 |
Similar Items
-
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
by: Roberto Pili, et al.
Published: (2010-08-01) -
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
by: Marinella Zilli, et al.
Published: (2013-07-01) -
Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
by: H. Miles Prince, et al.
Published: (2010-08-01) -
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
by: Monica Phimmachanh, et al.
Published: (2020-10-01) -
Histone deacetylase inhibitors
by: Marzena Baran, et al.
Published: (2020-08-01)